EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
PHOENIX, Feb. 7, 2013 /PRNewswire/ --EastBridge Investment Group Corporation (EBIG), a provider of financial consulting services to companies in Asia and the United States ("EBIG"), today announced that on February 6, EBIG and Cellular Biomedicine Group ("CBMG") executed all documentation and filed the Articles of Merger with the Registry of Corporate Affairs of the British Virgin Islands with respect to the consummation of the merger of CBMG with CBMG Acquisition Limited, a wholly-owned subsidiary of EBIG. The merged company is a wholly-owned subsidiary of EBIG. EBIG continues to operate under the corporate name "EastBridge Investment Group Corporation", a Delaware corporation, and its common stock continues to be quoted on the OTCQB under stock symbol "EBIGD".
A shareholder conference call is scheduled for February 8, 2013, at 11:00am EST, for questions and answers with the new corporate management team of EastBridge. Dial-in numbers for both domestic and international calls are listed below. You may also listen to a replay of the conference call by dialing the appropriate number and access code below. A replay of the conference call will be available on the company's website following the call.
Participants Dial-In Numbers
Toll-Free (US & Canada) (888) 390-3983
International (201) 604-5105
Dialing In For Conference Recording Playback
1. Dial 888-632-8973, or 585-295-6791 if you are calling from outside the USA.
2. At the system prompt, dial your replay code (80529152) followed by the # sign.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Ltd. develops proprietary cell therapies for the treatment of certain cancer and degenerative diseases. Our developmental stem cell, progenitor cell, and immune cell projects are the result of collaborative research and development between scientists and doctors from the U.S. and China. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
EastBridge Investment Group focuses on high-growth companies in Asia and in the United States, offering assistance with all aspects of IPOs, joint ventures and merchant banking services. EastBridge targets industries in the fields of electronics, real estate, auto, metal, energy, environmental, bioscience and retail food distribution. To learn more about EastBridge Investment Group go to our web site: www.EbigCorp.com. To receive EBIG's email alert, send a blank email to info@EbigCorp.com.
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although EastBridge and CBMG believe the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. Neither EastBridge nor CBMG has any obligation to update these forward-looking statements other than as required by law.
ProActive Capital Group
Director of Corporate Communications, CBMG
SOURCE EastBridge Investment Group Corporation
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.